p53/PD-L1 co-expression predicts poor prognosis in diffuse large B-cell lymphoma

Area of Science:

• Oncology
• Immunology
• Pathology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous hematologic malignancy.
• Understanding molecular markers like p53 and Programmed death-ligand 1 (PD-L1) is crucial for prognosis.
• The prognostic significance of p53 and PD-L1 co-expression in DLBCL requires further investigation.

Purpose of the Study:

• To evaluate the clinical characteristics and survival outcomes associated with p53 and PD-L1 co-expression in DLBCL patients.
• To assess the correlation between p53/PD-L1 co-expression and clinicopathological features.
• To determine the impact of Rituximab on DLBCL patients with p53/PD-L1 co-expression.

Main Methods:

• Immunohistochemistry (IHC) was employed to detect p53 and PD-L1 expression in 176 DLBCL tumor samples.
• Retrospective analysis of clinical data and long-term patient follow-up was conducted.
• Statistical methods were used to assess correlations and survival impacts.

Main Results:

• p53, PD-L1, and their co-expression were found in 44.9%, 42.0%, and 25.6% of DLBCL patients, respectively.
• p53/PD-L1 co-expression was more prevalent in non-germinal center B-cell-like (non-GCB) subtypes and positively correlated with PD-L1 expression.
• Patients with p53/PD-L1 co-expression exhibited significantly reduced progression-free survival (PFS) and overall survival (OS).

Conclusions:

• Co-expression of p53 and PD-L1 in DLBCL is an independent indicator of an adverse prognosis.
• DLBCL patients with p53/PD-L1 co-expression do not appear to benefit significantly from Rituximab therapy.
• Identifying this molecular subgroup is vital for risk stratification and potential therapeutic strategies.